Aquilo Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Aquilo Capital Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,194,237	Closed	-$23.6M	–	16
2021 Q2	$23.6M	Buy	1,194,237 +70,000	+6%	+$1.64M	6.12%	7
2021 Q1	$32.7M	Buy	1,124,237 +118,703	+12%	+$3.32M	5.91%	6
2020 Q4	$30.5M	Sell	1,005,534 -12,800	-1%	-$280K	6.33%	5
2020 Q3	$16.2M	Sell	1,018,334 -76,850	-7%	-$1.4M	1.72%	9
2020 Q2	$21.6M	Buy	1,095,184 +48,000	+5%	+$917K	4.36%	8
2020 Q1	$12.9M	Buy	+1,047,184	New	+$17.1M	5.03%	8

Other funds holding NGM

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Aquilo Capital Management's NGM Position: Q3 2021 in Review

Aquilo Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2021, closing a stake of 1,194,237 shares — an estimated $23.6M sold.

Aquilo Capital Management first reported a position in NGM in Q1 2020 and held it in 6 quarters. The position peaked at $32.7M in Q1 2021. 120 funds tracked by Wall St. Rank hold NGM as of Q3 2021.

Aquilo Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Aquilo Capital Management sold 1,194,237 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $23.6M.
Aquilo Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
Aquilo Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $32.7M in Q1 2021.
120 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Aquilo Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.